The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-100
SponsorGroupe Hospitalier du Havre

About this trial

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder that impairs motor neurons, with a life expectancy of 2 to 7 years after diagnosis. ALS manifests as 'spinal' when it primarily affects limbs, or 'bulbar' when it impairs speech and swallowing. The disease progressively weakens all skeletal muscles, causing respiratory issues and increased risk of lung infections due to ineffective coughing. Mechanical cough assistance via In-exsufflation therapy/ mechanical in-exsufflator devie (INEX/MI-E) applies positive and negative airway pressures non-invasively to improve coughing. However, MI-E may fail in some ALS patients due to airway collapse, often related to brainstem muscle dysfunction.Research by Andersen et al. in 2017 highlighted that during MI-E, ALS patients often experience adverse laryngeal movements, which can obstruct airways and reduce the therapy's effectiveness. To combat this, they suggested individualized MI-E settings to minimize airway collapse. Modern MI-E devices, such as the EOVE-70, offer adjustable positive expiratory pressure (PEP) between cycles to potentially enhance airway stability and coughing efficiency. The current study focuses on the impact of PEP during therapy pauses on the peak expiratory flow rate in ALS patients, which could lead to improved therapeutic outcomes.

Eligibility criteria

Qualifiers

Male or female patient aged over 18 years

Patient with Amyotrophic Lateral Sclerosis (ALS)

Patients with established or beginning bulbar disorders, identified by the healthcare team (speech impairment, hypersalivation, or swallowing difficulties)

Patient naive to INEX therapy but prescribed for its installation or patient already treated by an INEX device

Disqualifiers

Mental illness interfering with the proper use of the device

History of laryngospasm

Inability to come for consultation with the ALS team of the Groupe Hospitalier du Havre or the CHU of Dijon

Pregnancy

Trial design

Treatments tested in this trial

  • MI-E with PEP function activated during the pause
  • MI-E without PEP function activated during the pause

Treatment groups

11 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Groupe Hospitalier du Havre

Lead sponsor

French Physiotherapy Society / Société Français de Physiothérapie

Collaborator